Study of Suramin in Subjects With Furosemide-Resistant AKI
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, double-blind, randomized, placebo-controlled study to assess the
effects of suramin as a potential treatment option to prevent subjects with AKI from
progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis
dependent AKI.